Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C8H13N2O4S2.OTc |
| Molecular Weight | 379.33 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O=[Tc+3].[O-]C(=O)[C@H](CS)NCCN[C@@H](C[S-])C([O-])=O
InChI
InChIKey=NDEMJVQWTGORQT-USPAICOZSA-K
InChI=1S/C8H16N2O4S2.O.Tc/c11-7(12)5(3-15)9-1-2-10-6(4-16)8(13)14;;/h5-6,9-10,15-16H,1-4H2,(H,11,12)(H,13,14);;/q;;+3/p-3/t5-,6-;;/m0../s1
| Molecular Formula | OTc |
| Molecular Weight | 114.0 |
| Charge | 3 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C8H13N2O4S2 |
| Molecular Weight | 265.33 |
| Charge | -3 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.hindawi.com/journals/stni/2014/839369/Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/books/NBK215133/ | https://www.iaea.org/OurWork/ST/NE/NEFW/Technical-Areas/RRS/documents /mo99/WORKINGMATERIALSmo99CM.pdf | https://www.ncbi.nlm.nih.gov/pubmed/27854401
Sources: https://www.hindawi.com/journals/stni/2014/839369/
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/books/NBK215133/ | https://www.iaea.org/OurWork/ST/NE/NEFW/Technical-Areas/RRS/documents /mo99/WORKINGMATERIALSmo99CM.pdf | https://www.ncbi.nlm.nih.gov/pubmed/27854401
Molybdenum-99 (99Mo, half-life = 66 h) is a parent radionuclide of a diagnostic nuclear isotope. It decays in technetium-99 m (half-life = 6 h), which is used in over 30 million procedures per year around the world. Between 95 and 98 percent of Mo-99 is currently being produced using highly enriched uranium (HEU) targets. Other medical isotopes such as iodine-131 (I-131) and xenon-133 (Xe-133) are by-products of the Mo-99 production process and will be sufficiently available if Mo-99 is available.
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Diagnostic | OSTEOLITE Approved UseUnknown Launch Date1977 |
|||
| Diagnostic | DRAXIMAGE MDP-10 Approved UseMDP-25 (Kit for the Preparation of Technetium Tc 99m Medronate) may be used as a bone imaging agent to delineate areas of altered osteogenesis. Launch Date1978 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:39:59 GMT 2025
by
admin
on
Mon Mar 31 22:39:59 GMT 2025
|
| Record UNII |
2D30PH7DW4
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
V09CA06
Created by
admin on Mon Mar 31 22:39:59 GMT 2025 , Edited by admin on Mon Mar 31 22:39:59 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Technetium Tc 99m Ethylenedicysteine
Created by
admin on Mon Mar 31 22:39:59 GMT 2025 , Edited by admin on Mon Mar 31 22:39:59 GMT 2025
|
PRIMARY | |||
|
2D30PH7DW4
Created by
admin on Mon Mar 31 22:39:59 GMT 2025 , Edited by admin on Mon Mar 31 22:39:59 GMT 2025
|
PRIMARY | |||
|
134009-45-3
Created by
admin on Mon Mar 31 22:39:59 GMT 2025 , Edited by admin on Mon Mar 31 22:39:59 GMT 2025
|
SUPERSEDED | |||
|
154069-62-2
Created by
admin on Mon Mar 31 22:39:59 GMT 2025 , Edited by admin on Mon Mar 31 22:39:59 GMT 2025
|
PRIMARY | |||
|
155491280
Created by
admin on Mon Mar 31 22:39:59 GMT 2025 , Edited by admin on Mon Mar 31 22:39:59 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
||
|
|
ACTIVE MOIETY |
|